Citations

Clear

6273 citation(s) found for "To, Andrew".

NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification
Yoshida, Yasuyuki , Ozawa, Tomoko, Yao, Tsun-Wen, Wang, Shen , Brown, Dennis , Parsa, Andrew T., Raizer, Jeffrey J. , Cheng, Shi‐Yuan , Stegh, Alexander H. , Mazar, Andrew P. , Giles, Francis J., Butowski, Nicholas , Nicolaides, Theodore , James, C. David , Sarkaria, Jann N. , Cheng, Shi-Yuan , Nicolaides, Theodore

Mayo Clinic

Molecular Cancer Therapeutics | October 13, 2014 | Volume: 13 | Issue: 12 | Pages: 2919-2929

10.1158/1535-7163.mct-14-0306 | PMID 25313012 Get It

Abstract This report describes results from our analysis of the activity and biodistribution of a novel pan-ERBB inhibitor, NT113, when used in treating mice with intracranial glioblastoma (GBM) xenografts. Approaches used in this investigation include: bioluminescence imaging (BLI) for monitoring intracranial tumor growth and response to therapy; determination of survival benefit from treatment; analysis of tumor IHC reactivity for indication of treatment effect on proliferation and apoptotic response; Western blot analysis for determination of effects of treatment on ERBB and ERBB signaling mediator activation; and high-performance liquid chromatography for determination of NT113 concentration in tissue extracts from animals receiving oral administration of inhibitor. Our results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed. In experiments including lapatinib and/or erlotinib, NT113 treatment was associated with the most substantial improvement in survival, as well as the most substantial tumor growth inhibition, as indicated by BLI and IHC results. Western blot analysis results indicated that NT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on the phosphorylation of downstream signaling mediator Akt. Results from the analysis of animal tissues revealed significantly higher NT113 normal brain-to-plasma and intracranial tumor-to-plasma ratios for NT113, relative to erlotinib, indicating superior NT113 partitioning to intracranial tissue compartments. These data provide a strong rationale for the clinical investigation of NT113, a novel ERBB inhibitor, in treating patients with GBM. Mol Cancer Ther; 13(12); 2919–29. ©2014 AACR.
Thalidomide‐prednisone maintenance following autologous stem cell transplant for Multiple Myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10
Kovacs, Michael J., Davies, Gwynivere A , Chapman, Judy‐Anne W., Voralia, Michael, Roy, Jean , Kouroukis, C. Tom, Chen, Christine , Belch, Andrew R. , Reece, Donna , Zhu, Liting , Meyer, Ralph M., Shepherd, Lois E. , Stewart, Keith, Bahlis, Nizar Jacques

Mayo Clinic

British Journal of Haematology | October 10, 2014 | Volume: 168 | Issue: 4 | Pages: 511-517

10.1111/bjh.13176 | PMID 25302852 Get It

SummaryVenous thromboembolism (VTE) has an increased incidence in patients with multiple myeloma (MM), especially during chemotherapy. Mechanisms including upregulation of procoagulant factors, such as factor VIII, have been postulated. The National Cancer Institute of Canada Clinical Trials Group MY.10 phase III clinical trial compared thalidomide‐prednisone to observation for 332 patients with MM post‐autologous stem cell transplantation (ASCT), with a primary endpoint of overall survival and various secondary endpoints including the incidence of VTE. One hundred and fifty‐three patients had biomarker data, including D‐dimer, factor VIII and thrombin anti‐thrombin (TAT) levels collected post‐ASCT at baseline and 2 months after intervention investigating in‐vivo thrombin generation. Differences between the time‐points included a significant reduction over time in D‐dimer, factor VIII and TAT levels in the observation group and sustained elevation of D‐dimer, significant increase in factor VIII and reduction in TAT levels in the thalidomide‐prednisone group. Eight VTE events were reported in this subset of study patients, all in the thalidomide‐prednisone arm, with a trend to increase in D‐dimer levels over time in those patients with VTE. This study provides physiological and clinical evidence for an increased risk of VTE associated with thalidomide‐prednisone maintenance therapy post‐ASCT for MM.
A DRD1 Polymorphism Predisposes to Lung Cancer among Those Exposed to Secondhand Smoke during Childhood
Robles, Ana I. , Jen, Jin , McClary, Andrew C., Calhoun, Kara , Bowman, Elise D. , Vähäkangas, Kirsi, Wang, Yi , Olivo‐Marston, Susan , Wenzlaff, Angela S. , Deng, Bo , Schwartz, Ann G. , Yang, Ping , Greathouse, K Leigh , Ryan, Bríd M.

Mayo Clinic

Cancer Prevention Research | October 4, 2014 | Volume: 7 | Issue: 12 | Pages: 1210-1218

10.1158/1940-6207.capr-14-0158 | PMID 25281486 Get It

Abstract Lung cancer has a familial component which suggests a genetic contribution to its etiology. Given the strong evidence linking smoking with lung cancer, we studied miRNA-related loci in genes associated with smoking behavior. CHRNA, CHRNB gene families, CYP2A6, and DRD1 (dopamine receptor D1) were mined for SNPs that fell within the seed region of miRNA binding sites and then tested for associations with risk in a three-stage validation approach. A 3′UTR (untranslated region) SNP in DRD1 was associated with a lower risk of lung cancer among individuals exposed to secondhand smoke during childhood [OR, 0.69; 95% confidence interval (CI), 0.60–0.79; P < 0.0001]. This relationship was evident in both ever (OR, 0.74; 95% CI, 0.62–0.88; P = 0.001) and never smokers (OR, 0.61; 95% CI, 0.47–0.79; P < 0.0001), European American (OR, 0.65; 95% CI, 0.53–0.80; P < 0.0001), and African American (OR, 0.73; 95% CI, 0.62–0.88; P = 0.001) populations. Although much remains undefined about the long-term risks associated with exposure to secondhand smoke and heterogeneity between individuals in regard to their susceptibility to the effects of secondhand smoke, our data show an interaction between an SNP in the 3′UTR of DRD1 and exposure to secondhand smoke during childhood. Further work is needed to explore the mechanistic underpinnings of this SNP and the nature of the interaction between DRD1 and exposure to secondhand smoke during childhood. Cancer Prev Res; 7(12); 1210–8. ©2014 AACR.
A new muscle glycogen storage disease associated with glycogenin‐1 deficiency
Hedberg‐Oldfors, Carola , Hernández‐Laín, Aurelio , Michel, Fabrice , Domínguez‐González, Cristina , Viennet, G., Akman, Hasan O. , Kornblum, Cornelia , Romero, Norma B., DiMauro, Salvatore, Oldfors, Anders , Malfatti, Edoardo , Nilsson, Johanna E. , Bergh, Peter Y. K. Van den , Engel, Andrew G.

Mayo Clinic

Annals of Neurology | October 1, 2014 | Volume: 76 | Issue: 6 | Pages: 891-898

10.1002/ana.24284 | PMID 25272951 Get It

We describe a slowly progressive myopathy in 7 unrelated adult patients with storage of polyglucosan in muscle fibers. Genetic investigation revealed homozygous or compound heterozygous deleterious variants in the glycogenin‐1 gene (GYG1). Most patients showed depletion of glycogenin‐1 in skeletal muscle, whereas 1 showed presence of glycogenin‐1 lacking the C‐terminal that normally binds glycogen synthase. Our results indicate that either depletion of glycogenin‐1 or impaired interaction with glycogen synthase underlies this new form of glycogen storage disease that differs from a previously reported patient with GYG1 mutations who showed profound glycogen depletion in skeletal muscle and accumulation of glycogenin‐1. Ann Neurol 2014;76:891–898
Strategy for prevention of cancers of the esophagus
Akiyama, Junichi, Alexandre, Leo , Baruah, Anushka , Buttar, Navtej , Chandra, Raghav , Clark, Allan , Hart, Andrew , Hawk, Ernest T. , Kandioler, Daniela , Kappel, Sonja, Krishnadath, Sheila, Sharma, Anamay N. , Singh, Ishtpreet, Straub, Daniëlle, Triadafilopoulos, George , Wolf, Brigitte , Umar, Asad , Triadafilopoulos, George

Mayo Clinic

Annals of the New York Academy of Sciences | September 29, 2014 | Volume: 1325 | Issue: 1 | Pages: 108-126

10.1111/nyas.12529 | PMID 25266020 Get It

The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the animal reflux–inflammation models for Barrett's esophagus and esophageal adenocarcinoma; genomic/epigenomic analyses; eflornithine‐based combinations; the molecular derangements that promote neoplastic transformation; the role of COX‐2 inhibitors, proton pump inhibitors, and phase II trials in Barrett's adenocarcinoma; statins in chemoprevention and treatment of esophageal cancer; and biomarkers as potential targets in Barrett's adenocarcinoma.
Planar Cell Polarity Aligns Osteoblast Division in Response to Substrate Strain
Galea, Gabriel L. , Meakin, Lee B. , Savery, Dawn, Taipaleenmäki, Hanna , Delisser, Peter , Copp, Andrew J. , Wijnen, André J. van , Lanyon, Lance E., Price, Joanna S., Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Bone and Mineral Research | September 29, 2014 | Volume: 30 | Issue: 3 | Pages: 423-435

10.1002/jbmr.2377 | PMID 25264362 Get It

ABSTRACT Exposure of bone to dynamic strain increases the rate of division of osteoblasts and also influences the directional organization of the cellular and molecular structure of the bone tissue that they produce. Here, we report that brief exposure to dynamic substrate strain (sufficient to rapidly stimulate cell division) influences the orientation of osteoblastic cell division. The initial proliferative response to strain involves canonical Wnt signaling and can be blocked by sclerostin. However, the strain-related orientation of cell division is independently influenced through the noncanonical Wnt/planar cell polarity (PCP) pathway. Blockade of Rho-associated coiled kinase (ROCK), a component of the PCP pathway, prevents strain-related orientation of division in osteoblast-like Saos-2 cells. Heterozygous loop-tail mutation of the core PCP component van Gogh-like 2 (Vangl2) in mouse osteoblasts impairs the orientation of division in response to strain. Examination of bones from Vangl2 loop-tail heterozygous mice by µCT and scanning electron microscopy reveals altered bone architecture and disorganized bone-forming surfaces. Hence, in addition to the well-accepted role of PCP involvement in response to developmental cues during skeletal morphogenesis, our data reveal that this pathway also acts postnatally, in parallel with canonical Wnt signaling, to transduce biomechanical cues into skeletal adaptive responses. The simultaneous and independent actions of these two pathways appear to influence both the rate and orientation of osteoblast division, thus fine-tuning bone architecture to meet the structural demands of functional loading. © 2014 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
The neurologic significance of celiac disease biomarkers
McKeon, Andrew , Lennon, Vanda A. , Pittock, Sean J. , Kryzer, Thomas J., Murray, Joseph A. , Pittock, S J , McKeon, Andrew

Mayo Clinic

Neurology | September 26, 2014 | Volume: 83 | Issue: 20 | Pages: 1789-1796

10.1212/wnl.0000000000000970 | PMID 25261501 Get It

Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation
Sainski, Amy M., Dai, Haiming , Natesampillai, Sekar, Pang, Yuan‐Ping , Bren, Gary D., Correia, Cristina , Meng, X. Wei, Tarara, James E., Ramı́rez-Alvarado, Marina , Katzmann, David J. , Ochsenbauer, Christina , Kappes, John C. , Kaufmann, Scott H. , Badley, Andrew D. , Ramirez-Alvarado, Marina, Cummins, Nathan W. , Kaufmann, Scott H , Correia, Cristina , Ramirez-Alvarado, Marina , Badley, Andrew D , Pang, Yuan-Ping , Dai, Haiming

Mayo Clinic

Journal of Cell Biology | September 23, 2014 | Volume: 206 | Issue: 7 | Pages: 867-876

10.1083/jcb.201405051 | PMID 25246614 Get It

Previous studies have shown that human immunodeficiency virus (HIV) protease cleaves procaspase 8 to a fragment, termed Casp8p41, that lacks caspase activity but nonetheless contributes to T cell apoptosis. Herein, we show that Casp8p41 contains a domain that interacts with the BH3-binding groove of pro-apoptotic Bak to cause Bak oligomerization, Bak-mediated membrane permeabilization, and cell death. Levels of active Bak are higher in HIV-infected T cells that express Casp8p41. Conversely, targeted mutations in the Bak-interacting domain diminish Bak binding and Casp8p41-mediated cell death. Similar mutations in procaspase 8 impair the ability of HIV to kill infected T cells. These observations support a novel paradigm in which HIV converts a normal cellular constituent into a direct activator that functions like a BH3-only protein.
Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study
Davies, Benjamin M. , Rikabi, Sarah , French, Anna , Pinedo‐Villanueva, Rafael , Wartolowska, Karolina , Judge, Andrew , MacLaren, Robert E. , Mathur, Anthony , Williams, David , Wall, Ivan , Birchall, Martin , Reeve, Brock , Barker, Richard , Cui, Zhanfeng , Bure, Kim, Snyder, Evan Y., Carr, Andrew , Morrey, Mark E. , Atala, Anthony , Furniss, Dominic , Karp, Jeffrey M. , Price, Andrew James , Brindley, David A.

Mayo Clinic

Journal of Tissue Engineering | September 23, 2014 | Volume: 5 | Issue: No issue available | Pages: No page available

10.1177/2041731414551764 | PMID 25383173 Get It

There has been a large increase in basic science activity in cell therapy and a growing portfolio of cell therapy trials. However, the number of industry products available for widespread clinical use does not match this magnitude of activity. We hypothesize that the paucity of engagement with the clinical community is a key contributor to the lack of commercially successful cell therapy products. To investigate this, we launched a pilot study to survey clinicians from five specialities and to determine what they believe to be the most significant barriers to cellular therapy clinical development and adoption. Our study shows that the main concerns among this group are cost-effectiveness, efficacy, reimbursement, and regulation. Addressing these concerns can best be achieved by ensuring that future clinical trials are conducted to adequately answer the questions of both regulators and the broader clinical community.
Biomechanical aspects of trigger finger – which changed first, the pulley or the tendon?
Lu, Szu‐Ching , Su, Fong‐Chin , Zhao, Chunfeng , Thoreson, Andrew R. , Jou, I‐Ming , An, Kai‐Nan

Mayo Clinic

Journal of Biomechanical Science and Engineering | September 15, 2014 | Volume: 9 | Issue: 2 | Pages: 13-00237-13-00237

10.1299/jbse.13-00237 Get It